Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/lysosomal-storage-diseases-from-pathophysiology-to-therapy-twqvnP1Uvt
References (90)
-
Yunxiang Zhu, Xuemei Li, Josephine Kyazike, Qun Zhou, B. Thurberg, N. Raben, R. Mattaliano, Seng Cheng (2004)
Conjugation of Mannose 6-Phosphate-containing Oligosaccharides to Acid α-Glucosidase Improves the Clearance of Glycogen in Pompe Mice*Journal of Biological Chemistry, 279
-
D. Begley, Charlie Pontikis, M. Scarpa (2008)
Lysosomal storage diseases and the blood-brain barrier.Current pharmaceutical design, 14 16
-
B. Dehay, M. Martínez-Vicente, G. Caldwell, K. Caldwell, Zhenyu Yue, Mark Cookson, C. Klein, M. Vila, E. Bézard (2013)
Lysosomal impairment in Parkinson's diseaseMovement Disorders, 28
-
G. Parenti, G. Andria (2011)
Pompe disease: from new views on pathophysiology to innovative therapeutic strategies.Current pharmaceutical biotechnology, 12 6
-
N. Raben, Cynthia Schreiner, R. Baum, S. Takikita, Sengen Xu, Tao Xie, R. Myerowitz, M. Komatsu, J. Meulen, K. Nagaraju, E. Ralston, P. Plotz (2010)
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder—murine Pompe diseaseAutophagy, 6
-
P. Harmatz, R. Giugliani, I. Schwartz, N. Guffon, E. Teles, M. Miranda, J. Wraith, M. Beck, Laila Arash, M. Scarpa, Zi‐Fan Yu, J. Wittes, K. Berger, M. Newman, A. Lowe, E. Kakkis, S. Swiedler (2006)
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.The Journal of pediatrics, 148 4
-
M. Sands, B. Davidson (1998)
Gene therapy for lysosomal storage diseases.Molecular therapy : the journal of the American Society of Gene Therapy, 13 5
-
J. Muenzer, J. Wraith, M. Beck, R. Giugliani, P. Harmatz, C. Eng, A. Vellodi, Rick Martin, U. Ramaswami, M. Gucsavas-Calikoglu, S. Vijayaraghavan, Suzanne Wendt, A. Puga, B. Ulbrich, M. Shinawi, M. Cleary, D. Piper, A. Conway, A. Kimura (2006)
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genetics in Medicine, 8
-
O. Neudorfer, Nir Giladi, D. Elstein, A. Abrahamov, T. Turezkite, E. Aghai, A. Reches, B. Bembi, A. Zimran (1996)
Occurrence of Parkinson's syndrome in type I Gaucher disease.QJM : monthly journal of the Association of Physicians, 89 9
-
C. Settembre, A. Fraldi, D. Medina, A. Ballabio (2013)
Signals from the lysosome: a control centre for cellular clearance and energy metabolismNature Reviews Molecular Cell Biology, 14
-
Nikolaj Petersen, T. Kirkegaard (2010)
HSP70 and lysosomal storage disorders: novel therapeutic opportunities.Biochemical Society transactions, 38 6
-
A. Fraldi, Fabio Annunziata, A. Lombardi, H. Kaiser, D. Medina, C. Spampanato, Anthony Fedele, R. Polishchuk, N. Sorrentino, K. Simons, A. Ballabio (2010)
Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disordersThe EMBO Journal, 29
-
Wensi Song, Fan Wang, Marzia Savini, A. Aké, Alberto Ronza, Marco Sardiello, Laura Segatori (2013)
TFEB regulates lysosomal proteostasis.Human molecular genetics, 22 10
-
E. Lukina, N. Watman, Elsa Arreguin, M. Dragosky, M. Iastrebner, H. Rosenbaum, M. Phillips, Gregory Pastores, Ravi Kamath, Daniel Rosenthal, M. Kaper, Tejdip Singh, A. Puga, M. Peterschmitt (2010)
Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.Blood, 116 20
-
M. Muñoz-Rojas, T. Vieira, R. Costa, S. Fagondes, A. John, L. Jardim, L. Vedolin, Marcia Raymundo, P. Dickson, E. Kakkis, R. Giugliani (2008)
Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compressionAmerican Journal of Medical Genetics Part A, 146A
-
P. Dickson, M. Mcentee, C. Vogler, S. Le, B. Levy, M. Peinovich, Stephen Hanson, M. Passage, E. Kakkis (2007)
Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.Molecular genetics and metabolism, 91 1
-
R. Boado, Yu-feng Zhang, Yun Zhang, Chun‐fang Xia, Yuntao Wang, W. Pardridge (2008)
Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.Bioconjugate chemistry, 19 3
-
G. Parenti (2009)
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinicsEMBO Molecular Medicine, 1
-
R. Lachmann (2011)
Enzyme replacement therapy for lysosomal storage diseasesCurrent Opinion in Pediatrics, 23
-
Marco Sardiello, M. Palmieri, Alberto Ronza, D. Medina, M. Valenza, V. Gennarino, Chiara Malta, Francesca Donaudy, V. Embrione, R. Polishchuk, S. Banfi, G. Parenti, E. Cattaneo, A. Ballabio (2009)
A Gene Network Regulating Lysosomal Biogenesis and FunctionScience, 325
-
E. Lloyd-Evans, A. Morgan, Xingxuan He, David Smith, Elena Elliot-Smith, D. Sillence, G. Churchill, E. Schuchman, A. Galione, F. Platt (2008)
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calciumNature Medicine, 14
-
H. Hout, A. Reuser, A. Vulto, M. Loonen, A. Cromme-Dijkhuis, A. Ploeg (2000)
Recombinant human α-glucosidase from rabbit milk in Pompe patientsThe Lancet, 356
-
Y. Meng, I. Sohar, D. Sleat, J. Richardson, K. Reuhl, R. Jenkins, G. Sarkar, P. Lobel (2014)
Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain.Molecular therapy : the journal of the American Society of Gene Therapy, 22 3
-
R. Zoncu, L. Bar-Peled, A. Efeyan, Shuyu Wang, Y. Sancak, D. Sabatini (2011)
mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPaseScience, 334
-
T. Kirkegaard, A. Roth, Nikolaj Petersen, A. Mahalka, O. Olsen, Irina Moilanen, Alicja Zylicz, J. Knudsen, K. Sandhoff, C. Arenz, P. Kinnunen, Jesper Nylandsted, M. Jäättelä (2010)
Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathologyNature, 463
-
N. Barton, F. Furbish, G. Murray, M. Garfield, R. Brady (1990)
Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.Proceedings of the National Academy of Sciences of the United States of America, 87 5
-
S. Reggi, S. Marchetti, Tamara Patti, F. Amicis, R. Cariati, B. Bembi, C. Fogher (2004)
Recombinant human acid β-glucosidase stored in tobacco seed is stable, active and taken up by human fibroblastsPlant Molecular Biology, 57
-
T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. Weely, M. Hřebíček, F. Platt, T. Butters, R. Dwek, C. Moyses, I. Gow, D. Elstein, A. Zimran (2000)
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 355
-
D. Medina, A. Fraldi, V. Bouché, Fabio Annunziata, G. Mansueto, C. Spampanato, C. Puri, Antonella Pignata, J. Martina, Marco Sardiello, M. Palmieri, R. Polishchuk, R. Puertollano, A. Ballabio (2011)
Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular ClearanceDevelopmental Cell, 21
-
Sean Prater, S. Banugaria, Stephanie Dearmey, Eleanor Botha, Erin Stege, L. Case, Harrison Jones, C. Phornphutkul, Raymond Wang, S. Young, P. Kishnani (2012)
The emerging phenotype of long-term survivors with infantile Pompe diseaseGenetics in Medicine, 14
-
A. Zimran, E. Brill‐Almon, R. Chertkoff, M. Petakov, F. Blanco‐Favela, E. Muñoz, S. Solorio-Meza, D. Amato, Gloria Durán, F. Giona, R. Heitner, H. Rosenbaum, P. Giraldo, A. Mehta, Glen Park, M. Phillips, D. Elstein, G. Altarescu, Mali Szleifer, S. Hashmueli, D. Aviezer (2011)
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.Blood, 118 22
-
Qing-hui Zhou, R. Boado, Jeff Lu, E. Hui, W. Pardridge (2012)
Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the MouseDrug Metabolism and Disposition, 40
-
K. Ponder (2008)
Immune response hinders therapy for lysosomal storage diseases.The Journal of clinical investigation, 118 8
-
E. Kakkis, J. Muenzer, G. Tiller, L. Waber, J. Belmont, M. Passage, Barbara Izykowski, Jeffrey Phillips, R. Doroshow, I. Walot, R. Hoft, E. Neufeld (2001)
Enzyme-replacement therapy in mucopolysaccharidosis I.The New England journal of medicine, 344 3
-
N. Barton, R. Brady, J. Dambrosia, A. Bisceglie, S. Doppelt, S. Hill, H. Mankin, G. Murray, R. Parker, C. Argoff, R. Grewal, Kian-Ti Yu (1991)
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.The New England journal of medicine, 324 21
-
W. Sly, H. Fischer (1982)
The Phosphomannosyl Recognition System for Intracellular and Intercellular Transport of Lysosomal EnzymesJournal of Cellular Biochemistry, 18
-
Ian Williams, Kerri-Lee Wallom, David Smith, N. Eisa, Claire Smith, F. Platt (2014)
Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann–Pick disease type C1 miceNeurobiology of Disease, 67
-
G. Parenti, M. Moracci, S. Fecarotta, G. Andria (2014)
Pharmacological chaperone therapy for lysosomal storage diseases.Future medicinal chemistry, 6 9
-
M. Fuller, P. Meikle, J. Hopwood (2006)
Epidemiology of lysosomal storage diseases: an overview -
Ting-Wei Mu, D. Ong, Ya-Juan Wang, W. Balch, J. Yates, Laura Segatori, J. Kelly (2008)
Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding DiseasesCell, 134
-
R. Schiffmann, J. Kopp, H. Austin, S. Sabnis, D. Moore, T. Weibel, J. Balow, R. Brady (2001)
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA, 285 21
-
D. Koeberl, S. Austin, L. Case, E. Smith, A. Buckley, S. Young, D. Bali, P. Kishnani (2014)
Adjunctive albuterol enhances the response to enzyme replacement therapy in late‐onset Pompe diseaseThe FASEB Journal, 28
-
M. Patterson, D. Vecchio, Helena Prady, L. Abel, J. Wraith (2007)
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled studyThe Lancet Neurology, 6
-
R. Schiffmann (2010)
Agalsidase treatment for Fabry disease: Uses and rivalriesGenetics in Medicine, 12
-
P. Orchard, B. Blazar, J. Wagner, L. Charnas, W. Krivit, J. Tolar (2007)
Hematopoietic cell therapy for metabolic disease.The Journal of pediatrics, 151 4
-
D. Ong, Ya-Juan Wang, Yun Tan, J. Yates, Ting-Wei Mu, J. Kelly (2013)
FKBP10 depletion enhances glucocerebrosidase proteostasis in Gaucher disease fibroblasts.Chemistry & biology, 20 3
-
A. Nascimbeni, M. Fanin, E. Masiero, Corrado Angelini, Marco Sandri (2012)
The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII)Cell Death and Differentiation, 19
-
J. Maga, Jianghong Zhou, R. Kambampati, S. Peng, Xu Wang, R. Bohnsack, Angela Thomm, Sarah Golata, P. Tom, N. Dahms, B. Byrne, J. Lebowitz (2012)
Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice*The Journal of Biological Chemistry, 288
-
L. Shea, N. Raben (2009)
Autophagy in skeletal muscle: implications for Pompe disease.International journal of clinical pharmacology and therapeutics, 47 Suppl 1
-
C. Settembre, R. Zoncu, D. Medina, Francesco Vetrini, Serkan Erdin, S. Erdin, Tuong Huynh, Mathieu Ferron, G. Karsenty, M. Vellard, V. Facchinetti, D. Sabatini, A. Ballabio (2012)
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEBThe EMBO Journal, 31
-
Mark Osborn, R. McElmurry, Brandon Peacock, J. Tolar, B. Blazar (2008)
Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.Molecular therapy : the journal of the American Society of Gene Therapy, 16 8
-
T. Braulke, J. Bonifacino (2009)
Sorting of lysosomal proteins.Biochimica et biophysica acta, 1793 4
-
E. Kakkis, E. Kakkis, M. Mcentee, C. Vogler, S. Le, B. Levy, P. Belichenko, W. Mobley, P. Dickson, Stephen Hanson, M. Passage (2004)
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.Molecular genetics and metabolism, 83 1-2
-
Caterina Porto, A. Pisani, Margherita Rosa, E. Acampora, Valeria Avolio, M. Tuzzi, B. Visciano, C. Gagliardo, S. Materazzi, G. Marca, G. Andria, G. Parenti (2012)
Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry diseaseJournal of Inherited Metabolic Disease, 35
-
S. Banugaria, Sean Prater, Trusha Patel, Stephanie Dearmey, C. Milleson, Kathryn Sheets, D. Bali, C. Rehder, J. Raiman, Raymond Wang, F. Labarthe, J. Charrow, P. Harmatz, P. Chakraborty, A. Rosenberg, P. Kishnani (2013)
Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERTPLoS ONE, 8
-
J. Aharon-Peretz, H. Rosenbaum, R. Gershoni-baruch (2004)
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.The New England journal of medicine, 351 19
-
A. Biffi, E. Montini, L. Lorioli, M. Cesani, F. Fumagalli, T. Plati, C. Baldoli, S. Martino, A. Calabria, Sabrina Canale, F. Benedicenti, G. Vallanti, L. Biasco, Simone Leo, N. Kabbara, G. Zanetti, W. Rizzo, Nalini Mehta, M. Cicalese, Miriam Casiraghi, J. Boelens, U. Carro, D. Dow, M. Schmidt, A. Assanelli, Victor Neduva, C. Serio, E. Stupka, J. Gardner, C. Kalle, C. Bordignon, F. Ciceri, A. Rovelli, M. Roncarolo, A. Aiuti, M. Sessa, L. Naldini (2013)
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 341
-
C. Spampanato, Erin Feeney, Lishu Li, M. Cardone, Jeong-A Lim, Fabio Annunziata, H. Zare, R. Polishchuk, R. Puertollano, G. Parenti, A. Ballabio, N. Raben (2013)
Transcription factor EB (TFEB) is a new therapeutic target for Pompe diseaseEMBO Molecular Medicine, 5
-
J. Boelens, V. Prasad, J. Tolar, R. Wynn, C. Peters (2010)
Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.Pediatric clinics of North America, 57 1
-
P. Tiels, E. Baranova, K. Piens, C. Visscher, Gwenda Pynaert, W. Nerinckx, J. Stout, F. Fudalej, Paco Hulpiau, Simon Tännler, Steven Geysens, A. Hecke, Albena Valevska, W. Vervecken, H. Remaut, N. Callewaert (2012)
A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymesNature Biotechnology, 30
-
E. Benjamin, R. Khanna, A. Schilling, J. Flanagan, L. Pellegrino, N. Brignol, Y. Lun, D. Guillen, B. Ranes, M. Frascella, R. Soska, Jessie Feng, L. Dungan, Brandy Young, D. Lockhart, K. Valenzano (2012)
Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry MiceMolecular Therapy, 20
-
C. Settembre, A. Fraldi, Luca Jahreiss, C. Spampanato, C. Venturi, D. Medina, R. Pablo, C. Tacchetti, D. Rubinsztein, A. Ballabio (2008)
A block of autophagy in lysosomal storage disorders.Human molecular genetics, 17 1
-
Y. Sancak, L. Bar-Peled, R. Zoncu, Andrew Markhard, S. Nada, D. Sabatini (2010)
Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino AcidsCell, 141
-
N. Sorrentino, Luca D’Orsi, Irene Sambri, E. Nusco, Ciro Monaco, C. Spampanato, E. Polishchuk, Paola Saccone, E. Leonibus, A. Ballabio, A. Fraldi (2013)
A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIAEMBO Molecular Medicine, 5
-
F. Martiniuk, S. Reggi, K. Tchou-Wong, W. Rom, M. Busconi, C. Fogher (2013)
Production of a Functional Human Acid Maltase in Tobacco Seeds: Biochemical Analysis, Uptake by Human GSDII Cells, and In Vivo Studies in GAA Knockout MiceApplied Biochemistry and Biotechnology, 171
-
D. Anson, Chantelle McIntyre, S. Byers (2011)
Therapies for neurological disease in the mucopolysaccharidoses.Current gene therapy, 11 2
-
Jingyao Shen, Nancy Edwards, Y. Hong, G. Murray (2008)
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.Biochemical and biophysical research communications, 369 4
-
G. Parenti, S. Fecarotta, G. Marca, B. Rossi, S. Ascione, M. Donati, L. Morandi, S. Ravaglia, A. Pichiecchio, D. Ombrone, M. Sacchini, M. Pasanisi, P. Filippi, C. Danesino, R. Casa, A. Romano, C. Mollica, Margherita Rosa, Teresa Agovino, E. Nusco, Caterina Porto, G. Andria (2014)
A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.Molecular therapy : the journal of the American Society of Gene Therapy, 22 11
-
A. Lieberman, R. Puertollano, N. Raben, S. Slaugenhaupt, S. Walkley, A. Ballabio (2012)
Autophagy in lysosomal storage disordersAutophagy, 8
-
D. Auclair, J. Finnie, S. Walkley, Joleen White, Timothy Nielsen, M. Fuller, Alphonsus Cheng, C. O’Neill, J. Hopwood (2012)
Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI catsPediatric Research, 71
-
R. Khanna, J. Flanagan, Jessie Feng, R. Soska, M. Frascella, L. Pellegrino, Y. Lun, D. Guillen, D. Lockhart, K. Valenzano (2012)
The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe DiseasePLoS ONE, 7
-
Qun Zhou, J. Stefano, J. Harrahy, P. Finn, L. Avila, Josephine Kyazike, R. Wei, S. Patten, R. Gotschall, Xiaoyang Zheng, Yunxiang Zhu, T. Edmunds, C. Pan (2011)
Strategies for Neoglycan conjugation to human acid α-glucosidase.Bioconjugate chemistry, 22 4
-
D. Auclair, J. Finnie, Joleen White, Timothy Nielsen, M. Fuller, E. Kakkis, Alphonsus Cheng, C. O’Neill, J. Hopwood (2010)
Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.Molecular genetics and metabolism, 99 2
-
Caterina Porto, M. Cardone, Federica Fontana, B. Rossi, M. Tuzzi, A. Tarallo, M. Barone, G. Andria, G. Parenti (2009)
The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease FibroblastsMolecular Therapy: the Journal of the American Society of Gene Therapy, 17
-
J. Wraith (2006)
Limitations of enzyme replacement therapy: Current and futureJournal of Inherited Metabolic Disease, 29
-
K. Wyatt, W. Henley, Lindsey Anderson, Robert Anderson, V. Nikolaou, K. Stein, L. Klinger, D. Hughes, S. Waldek, R. Lachmann, A. Mehta, A. Vellodi, S. Logan (2012)
The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.Health technology assessment, 16 39
-
Obert, D. J., Esnick (2001)
UvA-DARE ( Digital Academic Repository ) Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry ' s disease -
Tamara Patti, B. Bembi, P. Cristin, F. Mazzarol, E. Secco, Carla Pappalardo, R. Musetti, M. Martinuzzi, S. Versolatto, R. Cariati, A. Dardis, S. Marchetti (2012)
Endosperm-specific expression of human acid beta-glucosidase in a waxy riceRice, 5
-
Janet Hsu, T. Bhowmick, S. Burks, J. Kao, S. Muro (2014)
Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.Journal of biomedical nanotechnology, 10 2
-
Annika Böckenhoff, S. Cramer, Philipp Wölte, S. Knieling, C. Wohlenberg, V. Gieselmann, H. Franke, U. Matzner (2014)
Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase AThe Journal of Neuroscience, 34
-
B. Dehay, M. Martínez-Vicente, A. Ramírez, C. Perier, C. Klein, M. Vila, E. Bézard (2012)
Lysosomal dysfunction in Parkinson diseaseAutophagy, 8
-
J. Grubb, C. Vogler, B. Levy, N. Galvin, Yun Tan, W. Sly (2008)
Chemically modified β-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VIIProceedings of the National Academy of Sciences, 105
-
D. Reczek, M. Schwake, Jenny Schröder, H. Hughes, Judith Blanz, Xiaoying Jin, W. Brondyk, S. Patten, T. Edmunds, P. Saftig (2007)
LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-GlucocerebrosidaseCell, 131
-
R. Brady (2006)
Enzyme replacement for lysosomal diseases.Annual review of medicine, 57
-
Adjunctive (cid:1) 2 -agonist treatment reduces glycogen independently of receptor-mediated acid (cid:2) -glucosidase uptake in the limb muscles of mice with Pompe disease -
S. Banugaria, Sean Prater, J. McGann, J. Feldman, Jesse Tannenbaum, Carrie Bailey, R. Gera, R. Conway, D. Viskochil, J. Kobori, A. Rosenberg, P. Kishnani (2012)
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe diseaseGenetics in Medicine, 15
-
Janet Hsu, L. Northrup, T. Bhowmick, S. Muro (2012)
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.Nanomedicine : nanotechnology, biology, and medicine, 8 5
-
Ha Huynh, J. Grubb, C. Vogler, W. Sly (2012)
Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VIIProceedings of the National Academy of Sciences, 109
-
K. Valenzano, R. Khanna, A. Powe, R. Boyd, Gary Lee, J. Flanagan, E. Benjamin (2011)
Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.Assay and drug development technologies, 9 3
-
E. Piotrowska, J. Jakóbkiewicz-Banecka, A. Tylki-Szymańska, A. Liberek, Agnieszka Maryniak, M. Malinowska, B. Czartoryska, E. Puk, A. Kloska, T. Liberek, S. Barańska, A. Węgrzyn, G. Węgrzyn (2008)
Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients.Current therapeutic research, clinical and experimental, 69 2
- Publisher
- Annual Reviews
- Copyright
- Copyright © 2015 by Annual Reviews. All rights reserved
- ISSN
- 0066-4219
- eISSN
- 1545-326X
- DOI
- 10.1146/annurev-med-122313-085916
- pmid
- 25587658
- Publisher site
- See Article on Publisher Site
Abstract
Lysosomal storage diseases are a group of rare, inborn, metabolic errors characterized by deficiencies in normal lysosomal function and by intralysosomal accumulation of undegraded substrates. The past 25 years have been characterized by remarkable progress in the treatment of these diseases and by the development of multiple therapeutic approaches. These approaches include strategies aimed at increasing the residual activity of a missing enzyme (enzyme replacement therapy, hematopoietic stem cell transplantation, pharmacological chaperone therapy and gene therapy) and approaches based on reducing the flux of substrates to lysosomes. As knowledge has improved about the pathophysiology of lysosomal storage diseases, novel targets for therapy have been identified, and innovative treatment approaches are being developed.
Journal
Annual Review of Medicine – Annual Reviews
Published: Jan 14, 2015